Competitive binding affinity to recombinant human galectin-1 after 5 mins in presence of fluorescent probe 3,3'-dideoxy-3-[4-(fluorescein-5-yl-carbonylaminomethyl)-1H-1,2,3-triazol-1-yl]-3'-(3,5-dimethoxy-benzamido)-1,1'-sulfanediyl-di-beta-D-galactopyranoside by fluorescence polarization assay
Competitive binding affinity to recombinant human galectin-2 after 5 mins in presence of fluorescent probe ,3'-dideoxy-3-[4-(fluorescein-5-yl-carbonylaminomethyl)-1H-1,2,3-triazol-1-yl]-3'-(3,5-dimethoxy-benzamido)-1,1'-sulfanediyl-di-beta-D-galactopyranoside by fluorescence polarization assay
Competitive binding affinity to recombinant human galectin-4 N-terminal after 5 mins in presence of fluorescent probe 3,3'-dideoxy-3-[4-(fluorescein-5-yl-carbonylaminomethyl)-1H-1,2,3-triazol-1-yl]-3'-(3,5-dimethoxy-benzamido)-1,1'-sulfanediyl-di-beta-D-galactopyranoside by fluorescence polarization assay
Competitive binding affinity to recombinant human galectin-4 C-terminal after 5 mins in presence of fluorescent probe 2-(fluorescein-5/6-yl-carbonyl)-aminoethyl 2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1-3)-[alpha-L-fucopyranosyl-(1-2)]-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranoside by fluorescence polarization assay
Competitive binding affinity to recombinant mouse galectin-7 after 5 mins in presence of fluorescent probe beta-D-galactopyranosyl(1-4)-2- acetamido-2-deoxy-beta-D-glucopyranosyl(1-3)-beta-D-galactopyranosyl(1-4)-(N1-fluorescein-5-yl-carbonylaminomethylcarbonyl)-beta-D-glucopyranosylamine by fluorescence polarization assay
Competitive binding affinity to recombinant human galectin-8 N-terminal after 5 mins in presence of fluorescent probe 2-(fluorescein-5-yl-carbonylamino)ethyl beta-D-galactopyranosyl(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranosyl(1-3)-beta-D-galactopyranosyl(1-4)-beta-D-glucopyranoside by fluorescence polarization assay
Competitive binding affinity to recombinant human galectin-9 N-terminal after 5 mins in presence of fluorescent probe 2-(fluorescein-5-yl-carbonylamino)ethyl-beta-D-galactopyranosyl(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranosyl(1-3)-beta-D-galactopyranosyl(1-4)-beta-D-glucopyranoside by fluorescence polarization assay
Competitive binding affinity to recombinant human galectin-9 C-terminal after 5 mins in presence of fluorescent probe 3,3'-dideoxy-3-[4-(fluorescein-5-yl-carbonylaminomethyl)-1H-1,2,3-triazol-1-yl]-3'-(3,5-dimethoxy-benzamido)-1,1'-sulfanediyl-di-beta-D-galactopyranoside by fluorescence polarization assay
Competitive binding affinity to recombinant human galectin-3 R144K mutant after 5 mins in presence of fluorescent probe 2-(fluorescein-5/6-yl-carbonyl)-aminoethyl 2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1-3)-[alpha-L-fucopyranosyl-(1-2)]-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranoside by fluorescence polarization assay
Competitive binding affinity to recombinant human galectin-3 R144S mutant after 5 mins in presence of fluorescent probe 2-(fluorescein-5/6-yl-carbonyl)-aminoethyl 2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1-3)-[alpha-L-fucopyranosyl-(1-2)]-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranoside by fluorescence polarization assay
Competitive binding affinity to recombinant human galectin-3 R186K mutant after 5 mins in presence of fluorescent probe beta-D-galactopyranosyl(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranosyl(1-3)-beta-D-galactopyranosyl(1-4)-(N1-fluorescein-5-yl-carbonylaminomethylcarbonyl)-beta-D-glucopyranosylamine by fluorescence polarization assay
Competitive binding affinity to recombinant human galectin-3 R186S mutant after 5 mins in presence of fluorescent probe 2-(fluorescein-5/6-yl-carbonyl)-aminoethyl 2-acetamido-2-deoxy-alpha-D-galactopyranosyl-(1-3)-[alpha-L-fucopyranosyl-(1-2)]-beta-D-galactopyranosyl-(1-4)-beta-D-glucopyranoside by fluorescence polarization assay
Competitive binding affinity to recombinant human galectin-3 K176L mutant after 5 mins in presence of fluorescent probe beta-D-galactopyranosyl(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranosyl(1-3)-beta-D-galactopyranosyl(1-4)-(N1-fluorescein-5-yl-carbonylaminomethylcarbonyl)-beta-D-glucopyranosylamine by fluorescence polarization assay
Anti-fibrotic activity in C57/Bl6 mouse bleomycin-induced lung fibrosis model assessed as reduction in total lung collagen levels at 3.5 mg/kg administered intratracheally as 4 doses every 48 hrs commencing on day 18 of bleomycin induction measured on day 26 post last dose relative to control
Anti-fibrotic activity in C57/Bl6 mouse bleomycin-induced lung fibrosis model assessed as reduction in total lung collagen levels at 0.35 to 1 mg/kg administered intratracheally as 4 doses every 48 hrs commencing on day 18 of bleomycin induction measured on day 26 post last dose
Anti-fibrotic activity in C57/Bl6 mouse bleomycin-induced lung fibrosis model assessed as reduction in fibrosis score at 3.5 mg/kg administered intratracheally as 4 doses every 48 hrs commencing on day 18 of bleomycin induction measured on day 26 post last dose by Masson's trichrome staining based assay relative to control
Effect on inflammatory score in bleomycin-induced C57/Bl6 mouse at 1 to 3.5 mg/kg administered intratracheally as 4 doses every 48 hrs commencing on day 18 of bleomycin induction measured on day 26 post last dose by Masson's trichrome staining based assay
Anti-fibrotic activity in C57/Bl6 mouse bleomycin-induced lung fibrosis model assessed as reduction in fibrosis score at 0.35 to 1 mg/kg administered intratracheally as 4 doses every 48 hrs commencing on day 18 of bleomycin induction measured on day 26 post last dose by Masson's trichrome staining based assay relative to control